

## DAFTAR PUSTAKA

Anh, L.T.N., M. V. Kumar, A., Ramaswamy, G., et al. 2020. High Levels of Treatment Success and Zero Relapse in Multidrug-Resistant Tuberculosis Patients Receiving a Levofloxacin-Based Shorter Treatment Regimen in Vietnam. *Trop Med Infect Dis.* 10;5(1):43.

Ateba-Ngoa, U., Edoa, J.R., Adegbite, B.R., et al. 2019. Implementation of multidrug-resistant tuberculosis (MDR-TB) treatment in Gabon: lessons learnt from the field. *Infection. Epub.* 47(5): 811–816.

Aung, K.J.M., Deun, A.V., Declercq, E., et al. 2014. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. *Int J Tuberc Lung Dis.* 18(10):1180-7.

Borisov, S., Danila, E., Maryandyshev, A., et al. 2019. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: First global report. *Eur. Respir. J.* 54(6):1901522.

Chiang, C.Y., Trébucq, A., Piubello, A., et al. 2018. Should gatifloxacin be included in the model list of essential medicines? *Eur. Respir. J.* 51.

Christoph, D.C., Jan H., Chi C., et al. 2018. Dru-resistant tuberculosis: An update on disease burden, diagnosis and treatment. *Official Journal of the Asia Pacific Society of Respiriology.* 23: 656-673.

Das, P.K and Ganguly, S.B., 2020. Effectiveness of the Shorter MDR Regimen in the Management of Tuberculosis: Shortfall in the Outcome of Disease a Multidimensional Approach and Evaluation for a Better Alternative. *Biomed Biotechnol Res J.* 4:143-7.

Grosset, J.H., Tyagi, S., Almeida, D.V., et al. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. *Am. J. Respir. Crit. Care Med.* 188: 608–612.

Gumbo, T., Louie, A., Parsons, L.M., et al. 2004. Selection of a moxifloxacin dose that suppresses drug resistance in *Mycobacterium tuberculosis*, by use of an in vitro

pharmacodynamic infection model and mathematical modeling. *J. Infect. Dis.* 190: 1642–1651.

Harouna, S.H., Ortuno-Gutierrez, N., Souleymane, M.B., et al. 2019. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger. *Int J Tuberc Dis.* 23(5):625–630.

Kemendes RI, 2020. *TB MDR Indonesia. TBC Indonesia.* URL: <https://tbindonesia.or.id/informasi/teknis/tb-mdr/> (diakses tanggal 10 Oktober 2020).

Kuaban, C., Noeske, J., Rieder, H.L., et al. 2015. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. *Int J Tuberc Lung Dis.* 19(5):517-24.

Lempens, P., Decroo, T., Aung, K.J.M., et al. 2020. Initial resistance to companion drugs should not be considered an exclusion criterion for the multidrug-resistant tuberculosis shorter treatment regimen. *International Journal of Infectious Diseases.* 100: 357-365.

Moodley, R., Godec, T.R., 2016. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. *European Respiratory Review.* 25: 29–35.

Nunn, A.J., Phillips, P.P.J., Meredith, S.K., et al. 2019. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. *N Engl J Med.* 380(13):1201-1213.

Piubello, A., Harouna, S.H., Souleymane, M.B., et al. 2014. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. *Int J Tuberc Lung Dis.* 18(10): 1188-94.

Trébucq, A., Schwoebel, V., Kashongwe, Z., et al. 2018. Treatment outcome with a short MDR-TB regimen among patients with rifampicin-resistant TB in nine African countries. *Int. J. Tuberc. Lung Dis.* 22: 17–25.

Van Deun, A., et al. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. *Am J Respir Crit Care Med.* Vol. 182(5): 684– 92.

Van Deun, A., Decroo, T., Piubello, A., et al. 2018. Principles for constructing a tuberculosis treatment regimen: The role and definition of core and companion drugs. *Int. J. Tuberc. Lung Dis.* 22: 239–245.

Wang, Q., Zhang, C., Guo, J., et al. 2015. Super-compact treatment with a high dose of moxifloxacin in patients with drug-resistant tuberculosis and its resistance mechanisms. *Experimental and therapeutic medicine.* 9(4): 1314–1318.


World Health Organization. 2016. *The Shorter MDR-TB Regimen.* URL: [https://www.who.int/tb/Short\\_MDR\\_regimen\\_factsheet.pdf](https://www.who.int/tb/Short_MDR_regimen_factsheet.pdf) (diakses tanggal 23 Oktober 2020).

World Health Organization. 2018. *What is Multidrug-resistant Tuberculosis and How do we control it?* URL: [https://www.who.int/westernpacific/news/q-a-detail/what-is-multidrug-resistant-tuberculosis-\(mdr-tb\)-and-how-do-we-control-it](https://www.who.int/westernpacific/news/q-a-detail/what-is-multidrug-resistant-tuberculosis-(mdr-tb)-and-how-do-we-control-it) (diakses tanggal 23 Oktober 2020).

World Health Organization. 2019. *Global Tuberculosis Report 2019.* WHO: Geneva, Switzerland.

World Health Organization. 2020. Tuberculosis. URL: <https://www.who.int/news-room/fact-sheets/detail/tuberculosis> (diakses tanggal 22 Oktober 2020).

## Lampiran 1. Dokumentasi Kegiatan



Go Get Gold PIMNAS 2020

File Edit Tampilan Sisipkan Format Alat Add-on Zotero Bantuan Terakhir diedit 7 menit lalu

Timeline

P : MDR-TB

**Timeline**


Selecting studies	03-07/09/20
Collecting Data	08-11/09/20
Meta-analysis	18-19/09/20
Quality assessment (ROBINS-E)	10-18/09/20
Penulisan paper	19-25/09/20
Finalisasi	26/09/20

P : MDR-TB  
E : Short-term therapy  
O :  
S : Observational study/Clinical

Keyword  
(((bangladesh regimen) OR ((short-term) OR (short term))) OR (short course)) AND  
(((multidrug-resistant tuberculosis) OR (multi-drug resistant tb)) OR (mdr tb))

Pubmed (02/09/20, 11:09 pm) = 438  
<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28%28bangladesh+regimen%29+OR+%28%28short-term%29+OR+%28short+term%29%29+OR+%28short+course%29%29+AND+%28%28%28multidrug-resistant+tuberculosis%29+OR+%28multi-drug+resistant+tb%29%29&page=1>

Menyusun rancangan detail review setelah melihat ketersediaan jurnal dan topik



Go Get Gold PIMNAS 2020

File Edit Tampilan Sisipkan Format Alat Add-on Zotero Bantuan Lihat perubahan baru

Timeline

P : MDR-TB

Science Direct (02/09/20, 11:...

DOAJ (03/09/20, 00:03 am) =...

NIH Clinical trial (03/09/20, 0...

Epistemikos (03/09/20, 00:...

Selecting Studies

Include : 10 + 1 = 11

**Selecting Studies**

Include	: 10 + 1	= 11
No Abstract	: 9	= 9
Wrong Language	: 7	= 7
Wrong Publication Year	: 222 + 1	= 223
Wrong Publication Type	: 23 + 6	= 29
Wrong Study Design	: 156 + 1	= 157
Wrong Population	: 26 + 1	= 27
Wrong Exposure	: 33 + 1	= 34
Duplicate	: 16 + 23	= 39
<b>Total</b>	<b>: 502 + 34</b>	<b>= 536</b>

Review Manager (RevMan)

Membahas hasil review abstrak dan lanjut ke full text untuk menyusun text

Participant	Sample size	Mean age/range	Recruit (follow-up) year	Exposure	Outcome	Success rate and failure	Adverse Event	Factors to unsuccessful outcome	Notes
MDR-TB previously untreated with second-line drugs	65	31 [16-66]	2008-2010	Phase Intensif 4 bulan: kanamycin (KM), prothionamide (PTN), isoniazid high dose (INH), high-dose rifampicin (RFX), Clofazimine (CFZ), Ethambutol (EMB), pyrazinamide (PZA) (Diarjut 6 bulan bila smear masih positif), fase Konfirmasi 8 bulan: OFI, OFZ, EMB dan PZA	Treatment outcome, Adverse drug reactions,	89% eight patients were declared cured (89.2%, 95%CI 81.7-95.7)	Vomiting (17), hearing loss (12), hyperglycemia (6), Severe (3), Artralgia (4), Depresi (3), Neuropati perifer (3), Siderosis kulit (2), Neuritis optik (2)	NA	1) Patients had second-line drug month and disseminated tuberculosis. Pregnant women were liver toxicity from
MDR-TB	515	12-78 tahun	2009-2008	Phase Intensif 4 bulan: high-dose rifampicin (RFX), Ethambutol (EMB), Pyrazinamide (PZA), Clofazimine (CFZ), kanamycin (KM), prothionamide (PTN), dan isoniazid (INH). Fase Konfirmasi 8 bulan: OFI, EMB, PZA, dan OFZ	Treatment success, Time required to complete treatment, Adverse drug events, Bacteriologic conversion among patients completing treatment, Risk factors for an unfavorable treatment outcome	Success rate 84.8% (435/515)	vomiting (111)	sex, and high-level fluoroquinolone (FQ) and Pyrazinamide (PZA) resistance	Patients were excluded from analysis if 1) culture identified only environmental mycobacteria and Mycobacterium tuberculosis was never isolated, 2) the patient had a history of previous treatment with second-line drugs, or 3) the adverse absorption. Risk to confirm RMP plus INH-resistant TB (i.e., MDR-TB).
MDR-TB	92	Group A (11.2557.56) Group B (11.1518.12)	2011-2013	Group A : moxifloxacin (0.6 g) moxifloxacin, rifampicin, pyrazinamide, isoniazid, ethambutol, and propylthiouracil (sopronitroly) aminine selama 6 bulan. Group B : moxifloxacin (0.4 g) selama obat yang sama dengan group A selama 8 bulan	curative rate, sputum negative conversion, food absorption and early closure, residual WBC, liver function damage, adverse reaction, level expression CCR5 and CCR4, and HLA-DR expression	the curative rate in group A was 82.61% and that in group B was 84.79%. There was no statistically significant difference in curative rate between the two groups (P>0.05)	Reduction of WBC Group A (2.17%) Group B (10.87%), Liver damage Group A (4.32%) Group B (10.87%), GI symptoms Group A (10.87%) Group B (10.49%), Neurological symptoms group A (13.04%) Group B (18.96%)		outcome of the Bangladesh regimen was largely maintained. Bacteriological treatment failures and relapses were rare, except among patients with high-level OFI resistance, notably in the presence of PZA resistance
									mendapatkan CAT selama 1 tahun dan (x) smear results, resisten pada pengobatan 2 CAT. Side effect mayat sleep pada obat yang digunakan dalam treatment ini, hasil TB paru terdeteksi

Diskusi *full text* jurnal

## Lampiran 2. Supplementary Data Seleksi Studi

### Timeline

Selecting studies	: 03-07/09/20
Collecting Data	: 08-11/09/20
Meta-analysis	: 18-19/09/20
Quality assessment (ROBINS-E)	: 10-18/09/20
Penulisan paper	: 19-25/09/20
Finalisasi	: 26/09/20

P : MDR-TB  
 E : Short-term therapy  
 O : -  
 S : Observational study/Clinical

### Keyword

**(((bangladesh regimen) OR ((short-term) OR (short term))) OR (short course)) AND (((multidrug-resistant tuberculosis) OR (multi-drug resistant tb)) OR (mdr tb))**

**Pubmed (02/09/20; 11:09 pm) = 442**

<https://pubmed.ncbi.nlm.nih.gov/?term=%28%28%28bangladesh+regimen%29+OR+%28%28short-term%29+OR+%28short+term%29%29+OR+%28short+course%29%29+AND+%28%28%28multidrug-resistant+tuberculosis%29+OR+%28multi-drug+resistant+tb%29%29+OR+%28mdr+tb%29%29&size=100&ac=no&sort=relevance>

**Science Direct (02/09/20; 11:42 pm) = 64**

<https://www.sciencedirect.com/search?qs=%22%22bangladesh%20regimen%22%20or%20%22short-course%22%20or%20%22short-term%22%22%20and%20%22%22mdr-tb%22%20or%20%22multidrug-resistant%20tuberculosis%22%22&show=100>

**DOAJ (03/09/20; 00.03 am) = 11**

[https://doaj.org/search?ref=homepage-box&source=%7B%22query%22%3A%7B%22query\\_string%22%3A%7B%22query%22%3A%22%5C%5C\(bangladesh%20regimen%5C%5C\)%20and%20%5C%5C\(multidrug%20resistant%20tuberculosis%5C%5C\)%20%22%2C%22default\\_operator%22%3A%22AND%22%7D%7D%7D](https://doaj.org/search?ref=homepage-box&source=%7B%22query%22%3A%7B%22query_string%22%3A%7B%22query%22%3A%22%5C%5C(bangladesh%20regimen%5C%5C)%20and%20%5C%5C(multidrug%20resistant%20tuberculosis%5C%5C)%20%22%2C%22default_operator%22%3A%22AND%22%7D%7D%7D)

1. <https://doaj.org/article/155ef19eb4f9474988cc5211243bafba>  
DUPLICATE
2. <https://doaj.org/article/17f42ee566a84c01bbfe8b6cedf37c4a> INCLUDE
3. <https://doaj.org/article/31f1fb6a08e74fa3b5a40a8e7044cd3f> WRONG  
STUDY DESIGN

4. <https://doaj.org/article/6947eef4bad94b24b9b3478be5e1a19c> > 10  
TAHUN
5. <https://doaj.org/article/6947eef4bad94b24b9b3478be5e1a19c>  
DUPLICATE
6. <https://doaj.org/article/6961b2e903334a6ab24bf30635d55f8f>  
DUPLICATE
7. <https://doaj.org/article/71eb95623bf643b3acd387ef5ba65545>  
DUPLICATE
8. <https://doaj.org/article/9990c8c7ff844e768520cf04e15caa89> DUPLICATE
9. <https://doaj.org/article/9b3c7f3e8adf49b393fb44380e17d2b3>  
DUPLICATE
10. <https://doaj.org/article/a3751eb09c1a4143a39252b09ec3c7a1>  
DUPLICATE
11. <https://doaj.org/article/ad83ab3636ff4c23bb9d364b43d9933e>  
DUPLICATE

**NIH Clinical trial (03/09/20; 00.12 am) = 9**

<https://clinicaltrials.gov/ct2/results?cond=Multidrug+Resistant+Tuberculosis&term=bangladesh+regimen&cntry=&state=&city=&dist=>

1. <https://clinicaltrials.gov/ct2/show/NCT02496572?term=bangladesh+regimen&cond=Multidrug+Resistant+Tuberculosis&draw=2&rank=1> WRONG PUBLICATION TYPE
2. <https://clinicaltrials.gov/ct2/show/NCT02975570?term=bangladesh+regimen&cond=Multidrug+Resistant+Tuberculosis&draw=2&rank=2> WRONG PUBLICATION TYPE

<https://clinicaltrials.gov/ct2/results?cond=Multi+Drug+Resistant+Tuberculosis&term=short-course&cntry=&state=&city=&dist=>

1. <https://clinicaltrials.gov/ct2/show/NCT02496572?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=1>  
DUPLICATE
2. <https://clinicaltrials.gov/ct2/show/NCT03057756?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=2>  
WRONG PUBLICATION TYPE
3. <https://clinicaltrials.gov/ct2/show/NCT03604848?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=3>  
WRONG PUBLICATION TYPE
4. <https://clinicaltrials.gov/ct2/show/NCT04062201?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=4>  
WRONG PUBLICATION TYPE
5. <https://clinicaltrials.gov/ct2/show/NCT01618422?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=5>  
WRONG POPULATION

6. <https://clinicaltrials.gov/ct2/show/NCT02274389?term=short-course&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=6>  
WRONG PUBLICATION TYPE

<https://clinicaltrials.gov/ct2/results?cond=Multi+Drug+Resistant+Tuberculosis&term=short-term&cntry=&state=&city=&dist=>

1. <https://clinicaltrials.gov/ct2/show/NCT01521364?term=short-term&cond=Multi+Drug+Resistant+Tuberculosis&draw=2&rank=1>  
WRONG EXPOSURE

**Epistemonikos (03/09/20; 00.16 am) = 14**

[https://www.epistemonikos.org/advanced\\_search?q=\(title:\(bangladesh%20regimen\)%20OR%20abstract:\(bangladesh%20regimen\)\)%20OR%20\(title:\(short-term\)%20OR%20abstract:\(short-term\)\)%20OR%20\(title:\(short-course\)%20OR%20abstract:\(short-course\)\)%20AND%20\(title:\(multidrug-resistant%20tuberculosis\)%20OR%20abstract:\(multidrug-resistant%20tuberculosis\)\)&protocol=no](https://www.epistemonikos.org/advanced_search?q=(title:(bangladesh%20regimen)%20OR%20abstract:(bangladesh%20regimen))%20OR%20(title:(short-term)%20OR%20abstract:(short-term))%20OR%20(title:(short-course)%20OR%20abstract:(short-course))%20AND%20(title:(multidrug-resistant%20tuberculosis)%20OR%20abstract:(multidrug-resistant%20tuberculosis))&protocol=no)

1. <https://www.epistemonikos.org/en/documents/ba84269abdb313437878e3716fd2e228faa46f1c> DUPLICATE
2. DUPLICATE
3. DUPLICATE
4. DUPLICATE
5. DUPLICATE
6. DUPLICATE
7. DUPLICATE
8. DUPLICATE
9. DUPLICATE
10. DUPLICATE
11. DUPLICATE
12. DUPLICATE
13. DUPLICATE
14. DUPLICATE

### **Selecting Studies**

Include	: 12	
No Abstract	: 9	= 9
Wrong Language	: 7	= 7
Wrong Publication Year	: 222 + 1	= 223
Wrong Publication Type	: 23 + 6 + 1	= 29 = 30
Wrong Study Design	: 156 + 1 + 1	= 157 = 158
Wrong Population	: 26 + 1	= 27
Wrong Exposure	: 33 + 1 + 1	= 34 = 35
Duplicate	: 16 + 23	= 39



**Total : 540**

Review Manager (RevMan)

**Pendahuluan**

- MDR-TB
- Masalah MDR-TB (Waktu terapi yang lama)

**Hasil**

- Hasil pencarian dan Penyaringan studi (PRISMA Chart)
- Karakteristik Studi Inklusi (Tabel karakteristik)
- Tingkat keberhasilan *short regimen* MDR-TB
- Faktor-faktor kegagalan *short regimen* MDR-TB
- *Adverse drug reaction*
- *Follow-up after treatment*

**Lampiran 3. Data Diri Peneliti*****CURRICULLUM VITAE***

Nama : Liani Elisabeth Enggy  
 Nama Panggilan : Liani  
 Tempat, Tanggal Lahir : Ujung Pandang, 17 Februari 1999  
 Jenis Kelamin : Perempuan  
 Agama : Katolik  
 Alamat : Jalan Monumen Emmy Saelan no. 25A  
 No. Telp : 082290359944  
 Email : lianienggy@gmail.com  
 Motto : “You are your only limit, vibe higher”

**Riwayat Pendidikan**

- a. SD : SD St. Joseph Rajawali Makassar
- b. SMP : SMP Frater Makassar
- c. SMA : SMA Rajawali Makassar
- d. Universitas : Fakultas Kedokteran Universitas Hasanuddin

**Riwayat Organisasi**

- 2018 – 2019** Anggota Membership and Development **Asian Medical Students’ Association (AMSA)** Fakultas Kedokteran Unhas
- 2018 – 2019** Anggota Research team **Asian Medical Students’ Association – Indonesia (AMSA)**
- 2018 – 2019** Anggota Departemen Science and Research **Medical Youth Research Club (MYRC)** Fakultas Kedokteran Unhas
- 2017 – Sekarang** Anggota **Orang Muda Katolik St. Fransiskus Asisi (OMK)**
- 2018 – Sekarang** Anggota **Lectio St. Fransiskus Asisi**
- 2019 – 2020** Asisten Dosen **Departemen Anatomi** Fakultas Kedokteran Universitas Hasanuddin

**Riwayat Kepanitiaan**

1. Anggota Divisi Acara Baksos KEMA FK Unhas 2018.
2. Koordinator Acara Asian Medical Student’s Exchange Program Indonesia x Thailand 2018
3. Chief of Delegation Musyawarah Nasional AMSA Indonesia 2018

4. Anggota Divisi Welcoming and Farewell Party National Action Event AMSA Indonesia 2018
5. Koordinator Acara Open Recruitment AMSA Unhas 2019
6. Anggota Divisi Liason Officer Hasanuddin Scientific Fair 2019
7. Mentor Basic Learning Skills Character and Creativity (BALANCE) Universitas Hasanuddin 2019
8. Anggota Divisi Acara Seminar Kewirausahaan BEM FK Unhas 2019
9. Anggota Divisi Acara Event Of The Year (EOTY) AMSA Unhas 2019
10. Steering Committee Open Recruitment AMSA Unhas 2020
11. Anggota Divisi Acara AORTA 2020
12. Steering Committe Hasanuddin Scientif Fair 2020

### **Riwayat Pelatihan**

1. Basic Student Leadership Training (BEM FK Unhas) 2017
2. Training of Trainer Basic Learning Skills Character and Creativity (BALANCE) Universitas Hasanuddin 2019
3. SDGs Coordinator academic session from SDSN Youth 2019

### **Prestasi Akademik dan Non Akademik**

1. Juara 2 Lomba Pidato Bahasa Inggris Sulsel UNM 2011
2. Juara 2 Duta Baca Pelajar Kota Makassar 2012
3. Juara 1 English Contest Se-kota Makassar SMK 8 2012
4. 2<sup>nd</sup> place winner of Story Telling Competition by Gramedia 2012
5. Finalist Literature Review Pasific Festival (Pasfest) Fakultas Kedokteran Universitas Padjajaran 2018
6. 2<sup>nd</sup> place white paper and video Pre PCC AMSC 2019 Singapore
7. Juara 2 Literature Review Hasanuddin Scientific Fair 2020
8. Juara 2 Literature Review Ar-razi Competition Unismuh 2020
9. Finalis pendanaan Program Kreativitas Mahasiswa cabang Penelitian Ekstakta (PKM-PE) 2020